CEQUA for Sjogren's Syndrome Dry Eye

Center for Ophthalmic and Vision Research, LLC50 enrolled

Overview

The primary objective of this study is to show that CEQUA (cyclosporine 0.09% ophthalmic solution) improves symptoms of dry eye disease in a population of patients with Sjogren's Syndrome diagnosis.

After being informed about the study and potential risks, all participants giving informed consent will have an eye exam and will be asked about their medical history to determine eligibility for the study. Eligible participants will continue to the second visit the same day or up to 10 days later. During the second visit participants will answer questionnaires about their eyes and have their vision, eyes, and tears examined. All participants will be given CEQUA to use over the duration of the study. The same procedures will be repeated every four weeks for 3 months total.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Dry Eye Dry Eye Syndromes Sjogren's Syndrome

Interventions

Cyclosporine 0.09% Ophthalmic SolutionDRUG

one drop each eye twice daily

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Clinical diagnosis of Sjogren's Syndrome. * Self-reported complaints of ocular dryness for a period of at least 3 months * Best-corrected distance visual acuity of 20/25 or better in each eye. Exclusion Criteria: * Use of cyclosporine within the last 3 months. * Use of ocular steroid within the 3 months. * Previous history of treatment failure with cyclosporine. * Known hypersensitivity or contraindication to the study medication or any of its ingredients. * Use of any systemic or topical ocular medication that is known to cause or exacerbate dry eye. * Any active ocular infection. * Severe or serious ocular condition in either eye or any other unstable medical condition that may preclude study treatment or follow-up. * History or presence of chronic generalized systemic disease that might increase the risk to the subject or confound the results of the study. * Currently pregnant or lactating.

Locations (1)

Center for Ophthalmic and Vision Recearch

Manhattan, New York, United States

Outcomes

Primary Outcomes

Mean change from baseline in total corneal staining

Expanded NEI corneal staining scale ranging from 0 to 15

Time frame: Baseline and week 12

Secondary Outcomes

Mean change from baseline in total conjunctival staining

Expanded NEI conjunctival staining scale ranging from 0 to 20

Time frame: Baseline and week 12

Mean change from baseline in the score of dry eye questionnaires

Dry eye questionnaire score ranging from 0 to 28

Time frame: Baseline and week 12

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.